Novel peptide calcitonin gene-related peptide antagonists for migraine therapy
Journal of Pharmacy and Pharmacology · 01.12.2023 · 75 (12) · 1581-1589
DOI: 10.1093/jpp/rgad081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 01.12.2023. Verfasst von Patrick M Killoran und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, United Kingdom. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK, Liverpool John Moores University, National Research, Development and Innovation Office of Hungary.
Abstract (Originalsprache)
Objectives
It has previously been shown that the peptide (34Pro,35Phe)CGRP27–37 is a potent calcitonin gene-related peptide, CGRP receptor antagonist, and in this project we aimed to improve the antagonist potency through the structural modification of truncated C-terminal CGRP peptides.
Methods
Six peptide analogues were synthesized and the anti-CGRP activity confirmed using both in vitro and in vivo studies. Key findings A 10 amino acid-containing peptide VPTDVGPFAF-NH2 (P006) was identified as a key candidate to take forward for in vivo evaluation, where it was shown to be an effective antagonist after intraperitoneal injection into mice. P006 was formulated as a preparation suitable for nasal administration by spray drying with chitosan to form mucoadhesive microcarriers (9.55 ± 0.91 mm diameter) and a loading of 0.2 mg peptide per 20 mg dose.
Conclusions
The project has demonstrated the potential of these novel small peptide CGRP antagonists, to undergo future preclinical evaluation as anti-migraine therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, United Kingdom.
- NHS Health Education England, Victoria House, Fulbourn, Cambridge, CB21 5XB, United Kingdom.
- AmbioPharm, Inc., 1024 Dittman Court, North Augusta, SC 29842, United States.
- EaStCHEM School of Chemistry, The University of Edinburgh, Joseph Black Building, David, Brewster Road, Edinburgh, EH14 4AS, United Kingdom.
- Department of Pharmacology and Pharmacotherapy, University of Pécs Medical School, Szigeti út 12, Pécs, Hungary.
- Eötvös Lorand Research Network, Chronic Pain Research Group, University of Pécs, Szigeti út 12, Pécs, Hungary.
ORCID-Profile: Gillian A Hutcheon
Förderung
- Innovate UK
- Liverpool John Moores University
- National Research, Development and Innovation Office of Hungary
- Eötvös Lóránd Research Network
Zitieren
APA
Killoran, P. M., Capel, V., D'Aloisio, V., Schofield, A., Aczél, T., Bölcskei, K., Helyes, Z., von Mentzer, B., Kendall, D. A., Coxon, C. R., & Hutcheon, G. A. (2023). Novel peptide calcitonin gene-related peptide antagonists for migraine therapy. Journal of Pharmacy and Pharmacology, 75(12), 1581-1589. https://doi.org/10.1093/jpp/rgad081
Vancouver
Killoran PM, Capel V, D'Aloisio V, Schofield A, Aczél T, Bölcskei K, et al. Novel peptide calcitonin gene-related peptide antagonists for migraine therapy. Journal of Pharmacy and Pharmacology. 2023;75(12):1581-1589. doi:10.1093/jpp/rgad081
BibTeX
@article{Killoran2023,
author = {Killoran, Patrick M and Capel, Vicky and D'Aloisio, Vera and Schofield, Adam and Aczél, Tímea and Bölcskei, Kata and Helyes, Zsuzsanna and von Mentzer, Bengt and Kendall, David A and Coxon, Chris R and Hutcheon, Gillian A},
title = {Novel peptide calcitonin gene-related peptide antagonists for migraine therapy},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
volume = {75},
number = {12},
pages = {1581--1589},
doi = {10.1093/jpp/rgad081}
}
EUVIMED